A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult Volunteers.

Trial Profile

A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult Volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs AV 7909 (Primary) ; Anthrax vaccine
  • Indications Anthrax
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Emergent BioSolutions
  • Most Recent Events

    • 12 Mar 2016 Results published in the Vaccine.
    • 24 Mar 2015 According to an Emergent BioSolutions media release, results from this study were presented at the ASM Biodefense and Emerging Diseases Research Meeting 2015.
    • 23 Feb 2015 The primary endpoints have been amended with the addition of 4 more safety endpoints.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top